Literature DB >> 25906160

DprE1 Is a Vulnerable Tuberculosis Drug Target Due to Its Cell Wall Localization.

Miroslav Brecik1, Ivana Centárová1, Raju Mukherjee2, Gaëlle S Kolly2, Stanislav Huszár1, Adela Bobovská1, Emöke Kilacsková1, Veronika Mokošová1, Zuzana Svetlíková1, Michal Šarkan1, João Neres2, Jana Korduláková1, Stewart T Cole2, Katarína Mikušová1.   

Abstract

The flavo-enzyme DprE1 catalyzes a key epimerization step in the decaprenyl-phosphoryl d-arabinose (DPA) pathway, which is essential for mycobacterial cell wall biogenesis and targeted by several new tuberculosis drug candidates. Here, using differential radiolabeling with DPA precursors and high-resolution fluorescence microscopy, we disclose the unexpected extracytoplasmic localization of DprE1 and periplasmic synthesis of DPA. Collectively, this explains the vulnerability of DprE1 and the remarkable potency of the best inhibitors.

Entities:  

Mesh:

Substances:

Year:  2015        PMID: 25906160     DOI: 10.1021/acschembio.5b00237

Source DB:  PubMed          Journal:  ACS Chem Biol        ISSN: 1554-8929            Impact factor:   5.100


  39 in total

1.  N-methylation of a bactericidal compound as a resistance mechanism in Mycobacterium tuberculosis.

Authors:  Thulasi Warrier; Kanishk Kapilashrami; Argyrides Argyrou; Thomas R Ioerger; David Little; Kenan C Murphy; Madhumitha Nandakumar; Suna Park; Ben Gold; Jianjie Mi; Tuo Zhang; Eugenia Meiler; Mike Rees; Selin Somersan-Karakaya; Esther Porras-De Francisco; Maria Martinez-Hoyos; Kristin Burns-Huang; Julia Roberts; Yan Ling; Kyu Y Rhee; Alfonso Mendoza-Losana; Minkui Luo; Carl F Nathan
Journal:  Proc Natl Acad Sci U S A       Date:  2016-07-18       Impact factor: 11.205

Review 2.  Peptidoglycan in Mycobacteria: chemistry, biology and intervention.

Authors:  Tripti Raghavendra; Saniya Patil; Raju Mukherjee
Journal:  Glycoconj J       Date:  2018-09-19       Impact factor: 2.916

3.  Spirocyclic and Bicyclic 8-Nitrobenzothiazinones for Tuberculosis with Improved Physicochemical and Pharmacokinetic Properties.

Authors:  Gang Zhang; Michael Howe; Courtney C Aldrich
Journal:  ACS Med Chem Lett       Date:  2019-02-23       Impact factor: 4.345

4.  Identification of Better Pharmacokinetic Benzothiazinone Derivatives as New Antitubercular Agents.

Authors:  Kai Lv; Xuefu You; Bin Wang; Zengquan Wei; Yun Chai; Bo Wang; Apeng Wang; Guocheng Huang; Mingliang Liu; Yu Lu
Journal:  ACS Med Chem Lett       Date:  2017-05-10       Impact factor: 4.345

Review 5.  Molecule Property Analyses of Active Compounds for Mycobacterium tuberculosis.

Authors:  Vadim Makarov; Elena Salina; Robert C Reynolds; Phyo Phyo Kyaw Zin; Sean Ekins
Journal:  J Med Chem       Date:  2020-04-20       Impact factor: 7.446

6.  Metabolism of SKLB-TB1001, a Potent Antituberculosis Agent, in Animals.

Authors:  Lu Xiong; Chao Gao; Yao-Jie Shi; Xin Tao; Cui-Ting Peng; Juan Rong; Kun-Lin Liu; Qian Lei; Yi-Wen Zhang; Ning-Yu Wang; Luo-Ting Yu
Journal:  Antimicrob Agents Chemother       Date:  2018-06-26       Impact factor: 5.191

7.  Deuteration of BTZ043 Extends the Lifetime of Meisenheimer Intermediates to the Antituberculosis Nitroso Oxidation State.

Authors:  Rui Liu; Viktor Krchnak; Seth N Brown; Marvin J Miller
Journal:  ACS Med Chem Lett       Date:  2019-08-29       Impact factor: 4.345

8.  Characterization of DprE1-Mediated Benzothiazinone Resistance in Mycobacterium tuberculosis.

Authors:  Caroline Shi-Yan Foo; Benoit Lechartier; Gaëlle S Kolly; Stefanie Boy-Röttger; João Neres; Jan Rybniker; Andréanne Lupien; Claudia Sala; Jérémie Piton; Stewart T Cole
Journal:  Antimicrob Agents Chemother       Date:  2016-10-21       Impact factor: 5.191

9.  Synthesis and Antitubercular Activity of New Benzo[b]thiophenes.

Authors:  Pravin S Mahajan; Mukesh D Nikam; Laxman U Nawale; Vijay M Khedkar; Dhiman Sarkar; Charansingh H Gill
Journal:  ACS Med Chem Lett       Date:  2016-06-28       Impact factor: 4.345

Review 10.  Inhibiting Mycobacterium tuberculosis within and without.

Authors:  Stewart T Cole
Journal:  Philos Trans R Soc Lond B Biol Sci       Date:  2016-11-05       Impact factor: 6.237

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.